Eledon Pharmaceuticals, Inc. (ELDN)

NCM – Real vaqt narxi. Valyuta: USD

2.83

-0.13 (-4.39%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

2.85

+0.02 (0.71%)

Bozordan keyin: Mar 27, 2026, 6:01 PM EDT

Kompaniya haqida

Eledon Pharmaceuticals, Inc. klinik bosqichdagi biotexnologiya kompaniyasi sifatida faoliyat yuritadi. U transplantatsiya qilingan organlarni himoya qilish va transplantatsiya rad etilishini oldini olish hamda amiotrofik lateral sklerozni (ALS) davolash uchun terapiyalarni ishlab chiqishda CD40 ligand (CD40L) yo'nalishiga qaratilgan immunologiya sohasidagi tajribasidan foydalanadi. Kompaniyaning ishlab chiqish bosqichidagi asosiy birikmasi tegoprubart, IgG1 va anti-CD40L antitelasi bo'lib, u CD40 ligandiga yuqori yaqinlikka ega, bu esa terapevtik potentsialga ega biologik maqsad hisoblanadi. Kompaniya o'z mahsulotlarini buyrak transplantatsiyasi va ksenotransplantatsiyada allograft rad etilishining oldini olish uchun ham ishlab chiqmoqda. Kompaniya eGenesis, Inc. bilan hamkorlik shartnomasiga ega; va NewcelX Ltd. bilan 1-to'rli diabet uchun NCEL-101 terapiyasini ishlab chiqish bo'yicha strategik hamkorlikni yo'lga qo'ygan. Kompaniya ilgari Novus Therapeutics, Inc. nomi bilan tanilgan va 2021 yil yanvar oyida Eledon Pharmaceuticals, Inc. nomini olgan. Eledon Pharmaceuticals, Inc. Kaliforniyaning Irvine shahrida joylashgan.

Asosiy rahbarlar

Ism	Lavozim
Dr. David Hovland Ph.D.	Chief Regulatory Officer
Dr. David-Alexandre C. Gros M.D., Ph.D.	CEO & Non Independent Director
Dr. Eliezer Katz F.A.C.S., M.D.	Chief Medical Officer
Dr. Steven N. Perrin Ph.D.	President, Chief Scientific Officer & Non Independent Director
Mr. Bryan E. Smith J.D.	General Counsel, Corporate Secretary & Chief Compliance Officer
Mr. John Herberger	Vice President of Technical Operations
Mr. Paul Sean Little	Chief Financial Officer